Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1186-91. doi: 10.1136/jnnp-2012-304740. Epub 2013 Apr 17.

Abstract

Objectives: To investigate the associations of serum lipid profile with disease progression in high-risk clinically isolated syndromes (CIS) after the first demyelinating event.

Methods: High density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were obtained in pretreatment serum from 135 high risk patients with CIS (≥ 2 brain MRI lesions and ≥ 2 oligoclonal bands) enrolled in the Observational Study of Early Interferon β-1a Treatment in High Risk Subjects after CIS study (SET study), which prospectively evaluated the effect of intramuscular interferon β-1a treatment following the first demyelinating event. Thyroid stimulating hormone, free thyroxine, 25-hydroxy vitamin D3, active smoking status and body mass index were also obtained. Clinical and MRI assessments were obtained within 4 months of the initial demyelinating event and at 6, 12 and 24 months.

Results: The time to first relapse and number of relapses were not associated with any of the lipid profile variables. Higher LDL-C (p=0.006) and TC (p=0.001) levels were associated with increased cumulative number of new T2 lesions over 2 years. Higher free thyroxine levels were associated with lower cumulative number of contrast-enhancing lesions (p=0.008). Higher TC was associated as a trend with lower baseline whole brain volume (p=0.020). Higher high density lipoprotein was associated with higher deseasonalised 1,25-dihydroxy vitamin D3 (p=0.003) levels and a trend was found for deseasonalised 25-hydroxy vitamin D3 (p=0.014).

Conclusions: In early multiple sclerosis, lipid profile variables particularly LDL-C and TC levels are associated with inflammatory MRI activity measures.

Keywords: Clinical Neurology; Mri; Multiple Sclerosis; Neurobiology; Neuroradiology.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Body Mass Index
  • Brain / drug effects
  • Brain / pathology
  • Calcifediol / blood
  • Cholesterol / blood*
  • Cholesterol, HDL / blood*
  • Cholesterol, LDL / blood*
  • Cohort Studies
  • Czech Republic
  • Demyelinating Diseases / blood
  • Demyelinating Diseases / drug therapy*
  • Early Medical Intervention
  • Female
  • Humans
  • Injections, Intramuscular
  • Interferon beta-1a
  • Interferon-beta / therapeutic use*
  • Longitudinal Studies
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy*
  • Prospective Studies
  • Smoking / adverse effects
  • Smoking / blood
  • Thyrotropin / blood
  • Thyroxine / blood
  • Young Adult

Substances

  • Adjuvants, Immunologic
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Interferon-beta
  • Thyrotropin
  • Cholesterol
  • Calcifediol
  • Thyroxine
  • Interferon beta-1a